204 related articles for article (PubMed ID: 9783598)
21. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
22. The effect of cytoprotective agents in platinum anticancer therapy.
Jakupec MA; Galanski M; Keppler BK
Met Ions Biol Syst; 2004; 42():179-208. PubMed ID: 15206103
[No Abstract] [Full Text] [Related]
23. Density functional theory and surface enhanced Raman spectroscopy characterization of novel platinum drugs.
Giese B; Deacon GB; Kuduk-Jaworska J; McNaughton D
Biopolymers; 2002; 67(4-5):294-7. PubMed ID: 12012451
[TBL] [Abstract][Full Text] [Related]
24. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity.
Calvert H; Judson I; van der Vijgh WJ
Cancer Surv; 1993; 17():189-217. PubMed ID: 8137341
[TBL] [Abstract][Full Text] [Related]
25. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
Brabec V; Nováková O
Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin and platinum drugs at the molecular level. (Review).
Boulikas T; Vougiouka M
Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.
Verschraagen M; Boven E; Torun E; Erkelens CA; Hausheer FH; van der Vijgh WJ
Br J Cancer; 2004 Apr; 90(8):1654-9. PubMed ID: 15083199
[TBL] [Abstract][Full Text] [Related]
28. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N.
Hausheer FH; Parker AR; Petluru PN; Jair KW; Chen S; Huang Q; Chen X; Ayala PY; Shanmugarajah D; Kochat H
Cancer Chemother Pharmacol; 2011 Feb; 67(2):381-91. PubMed ID: 20440617
[TBL] [Abstract][Full Text] [Related]
29. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Selvaggi G; Belani CP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
[TBL] [Abstract][Full Text] [Related]
30. Future directions in gynecologic cancer.
Alberts DS
Semin Oncol; 1999 Apr; 26(2 Suppl 7):125-8. PubMed ID: 10348271
[TBL] [Abstract][Full Text] [Related]
31. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M;
Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762
[TBL] [Abstract][Full Text] [Related]
32. Platinum-based anticancer agents: innovative design strategies and biological perspectives.
Ho YP; Au-Yeung SC; To KK
Med Res Rev; 2003 Sep; 23(5):633-55. PubMed ID: 12789689
[TBL] [Abstract][Full Text] [Related]
33. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
Verschraagen M; Boven E; Zegers I; Hausheer FH; Van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Jun; 51(6):525-9. PubMed ID: 12750838
[TBL] [Abstract][Full Text] [Related]
35. DNA interactions of new cytotoxic tetrafunctional dinuclear platinum complex trans,trans-[{PtCl2(NH3)}2(piperazine)].
Brabec V; Christofis P; Slámová M; Kostrhunová H; Nováková O; Najajreh Y; Gibson D; Kaspárková J
Biochem Pharmacol; 2007 Jun; 73(12):1887-900. PubMed ID: 17400194
[TBL] [Abstract][Full Text] [Related]
36. Administration of the cytoprotectant amifostine.
Lindemann K
Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
[TBL] [Abstract][Full Text] [Related]
37. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
38. Modern methods for diagnosis and monitoring of nephrotoxicity during antitumor therapy with platinum derivatives.
Lyubimova NV; Topchieva SV; Averinova SG; Kashkadaeva AV; Gorbunova VA; Shiryaev SV; Kushlinskii NE
Bull Exp Biol Med; 2000 Sep; 130(9):886-91. PubMed ID: 11177273
[TBL] [Abstract][Full Text] [Related]
39. [Anticancer drugs used in medicine and being in clinical research].
Malinowska K; Modranka R; Kedziora J
Pol Merkur Lekarski; 2007 Sep; 23(135):165-9. PubMed ID: 18080687
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin: a review of toxicities and therapeutic applications.
Barabas K; Milner R; Lurie D; Adin C
Vet Comp Oncol; 2008 Mar; 6(1):1-18. PubMed ID: 19178659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
